April #80 : Get SMART - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Tweedledum and Dumber

Hip to the Future

High Society

Pride & Prejudice

Weekend Warrior

Bad Bio-Rad

Don't Fence Me In

War Cries

Heavy Petting

Pass the Lube

Obit: Lance Loud

Living Spoof

Babes in Tube-Land

Altered States

A Tell-All About T Cells

Quick Draw


KS Dating

Cancer Count


Let's Roll...Back!

Scumbag Humbug

Editor's Letter


Larry's Lease on Life

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

April 2002


by Lark Lands

Hit early, hit hard" was yesterday's HAART mantra. Now, thanks to side effects and resistance, "Go slow" may be tomorrow's motto. But how slow is too slow? Federal bigwig Anthony Fauci, MD, said, "To strike a balance between adequately aggressive treatment and minimal adverse side effects, we need hard data."

That's why the government is funding the SMART (Strategies for Management of Anti-Retroviral Therapies) trial. And it's a big one. A network of community-based researchers, the CPCRA (Community Programs for Clinical Research on AIDS), will enroll 6,000 HIVers who will be monitored for an average of seven years. Half will be randomly assigned to the Viral Suppression (VS) group, where docs and their patients will be encouraged to use any and all drugs necessary to keep viral load as low as possible for as long as possible, following the current guidelines. The Defer or Delay Change (DC) half will be asked to hold off on HAART until their CD4 count goes below 250 -- a point, according to the University of Minnesota's Carlton Hogan, MD, one of the SMARTies who designed the trial, high enough so that opportunistic infections are unlikely but low enough that, if HIVers remain untreated, problems will develop in a year or two. "The hope is to ensure patient safety in the DC group, while sparing drugs for as long as possible," he says. If CD4s bounce back above 350, DCers will be encouraged to drop the drugs again -- until CD4s fall back to 250.

Comparison of early/continuous vs. late/intermittent will clarify the current quandary on when to start HAART, when to switch and which factors predict disease progression and the rates of side effects. Then we can all SMARTen up.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.